<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02668406</url>
  </required_header>
  <id_info>
    <org_study_id>Melioidosis</org_study_id>
    <nct_id>NCT02668406</nct_id>
  </id_info>
  <brief_title>Study to Obtain Blood and Voided Urine Samples to Improve the Diagnosis of Melioidosis</brief_title>
  <official_title>Establishment of a Reference Clinical Sample Panel Allowing for the Development and Proof-of-concept Validation of an In-vitro Diagnostic Test for the Diagnosis of Melioidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Tropical Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sihanouk Hospital Center of HOPE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SRI International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Tropical Medicine, Belgium</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical samples [blood and voided urine (only for phase A)] from patient recruited at
      Sihanouk Hospital Centre of HOPE (SHCH) and HOPE Community Medical Center (CMC) will be
      processed (decontamination) and shipped to SRI International with the purpose of design and
      validation (proof of concept) and (case/control series) of in-vitro diagnostics for
      melioidosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study will be proposed to all patients at Sihanouk Hospital Centre of HOPE (SHCH) and HOPE
      Community Medical Center (CMC) presenting with systemic inflammatory response syndrome
      (SIRS).

      Blood samples will be collected upon admission for patients with blood culture request as
      part of routine patient care and agreement on informed consent. A second sample will be
      collected in patients with blood culture proven melioidosis or suspicion of melioidosis (only
      for phase B), at day 5 after initiation of appropriate antibiotic treatment. Depending on the
      final diagnosis, a subset of patients will be assigned to 3 groups:

        1. Patients for whom blood cultures grew Burkholderia pseudomallei

        2. Patients for whom blood cultures did not grow a pathogen, but have other body site grown
           with Burkholderia pseudomallei, or are suspected of melioidosis

        3. Patients for whom blood cultures grew with another pathogen

      In phase A only, at least 20 ml of voided urine will be collected when a patient is
      hospitalized and identified as belonging to study group 1, 2 or 3. A second collection of
      voided urine will be collected for group 1 and 2 patients during routine further hospital
      stay or a routine follow-up visit.

      The clinical samples from these patients will be processed and shipped to SRI International
      with the purpose of design (=phase A) and validation (=phase B) of in-vitro diagnostics for
      melioidosis.

      A coded database will be completed with basic demographic, clinical and microbiological data
      and final diagnosis. This coded information will be provided to SRI International.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical reference panel (blood)</measure>
    <time_frame>15 months</time_frame>
    <description>Establishment of a quality-assured and well-documented clinical reference panel (cases/control) of human blood samples allowing for the design, development and proof-of-concept validation of an in-vitro diagnostic assay for the diagnosis of melioidosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical reference panel (urine)</measure>
    <time_frame>15 months</time_frame>
    <description>Establishment of a quality-assured and well-documented clinical reference panel (cases/control) of human voided urine samples allowing for the design, development and proof-of-concept validation of an in-vitro diagnostic assay for the diagnosis of melioidosis.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">3600</enrollment>
  <condition>Melioidosis</condition>
  <condition>Systemic Inflammatory Response Syndrome</condition>
  <condition>Suspected or Confirmed Bloodstream Infections</condition>
  <arm_group>
    <arm_group_label>Burkholderia pseudomallei</arm_group_label>
    <description>Patients for whom blood cultures grew Burkholderia pseudomallei</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No pathogen</arm_group_label>
    <description>Patients for whom blood cultures did not grow a pathogen, but have other body site grown with Burkholderia pseudomallei, or are suspected of melioidosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Another pathogen</arm_group_label>
    <description>Patients for whom blood cultures grew another pathogen</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Venous blood sampling (2 timepoints) (Phase A and B)</intervention_name>
    <description>8.5ml at Day 1 + 8.5ml at Day 5</description>
    <arm_group_label>Burkholderia pseudomallei</arm_group_label>
    <arm_group_label>No pathogen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Venous blood sampling (1 timepoint) (Phase A and B)</intervention_name>
    <description>8.5ml at Day 1</description>
    <arm_group_label>Another pathogen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Voided urine sampling (first sample) (Phase A)</intervention_name>
    <description>At least 20ml upon confirmation of being part of one of the 3 study groups</description>
    <arm_group_label>Burkholderia pseudomallei</arm_group_label>
    <arm_group_label>No pathogen</arm_group_label>
    <arm_group_label>Another pathogen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Voided urine sampling (second sample) (Phase A)</intervention_name>
    <description>At least 20ml during routine hospital stay or routine follow-up visit</description>
    <arm_group_label>Burkholderia pseudomallei</arm_group_label>
    <arm_group_label>No pathogen</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood (phase A and B) and voided urine samples (only phase A)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients presenting with systemic inflammatory response syndrome.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (&gt;18 years old)

          -  Blood culture request by treating physician as part of standard care

          -  Willing to give informed consent

        Exclusion Criteria:

          -  Refusal to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Jacobs, MD</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Tropical Medicine, Antwerp, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thong Phe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sihanouk Hospital Center of HOPE (SHCH), Cambodia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Jacobs, MD</last_name>
    <phone>+32(0)32476630</phone>
    <email>jjacobs@itg.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marjan Peeters, MSc</last_name>
    <phone>+32(0)33455788</phone>
    <email>mpeeters@itg.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HOPE Community Medical Center</name>
      <address>
        <city>Phnom Penh</city>
        <country>Cambodia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thong Phe, MD</last_name>
      <phone>(855) 12 953 905</phone>
      <email>thongphe@sihosp.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sihanouk Hospital Center of HOPE (SHCH), Cambodia</name>
      <address>
        <city>Phnom Penh</city>
        <country>Cambodia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thong Phe, MD</last_name>
      <phone>(855) 12 953 905</phone>
      <email>thongphe@sihosp.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Cambodia</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2016</study_first_submitted>
  <study_first_submitted_qc>January 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2016</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood infection, melioidosis, rapid diagnostic test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
    <mesh_term>Melioidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

